Undisclosed CDK2-Cyclin E precision therapeutic / Cedilla Therap, Bayer - LARVOL DELTA

Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology (Businesswire) - "Bayer and Cedilla Therapeutics...announced an exclusive license agreement to develop and commercialize Cedilla Therapeutics’ CyclinE1/CDK2 complex inhibitors which selectively address oncogenic drivers....Assets are currently in pre-clinical development with potential to serve patients with high unmet need in underserved indications....Under the terms of the agreement, Bayer will receive full rights on the development and commercialization of Cedilla’s CyclinE1/CDK2 complex inhibitors. Cedilla will receive an upfront payment and potential development and commercial-based milestone payments. Cedilla will also be eligible to receive royalties on medicines based on their technology commercialized by Bayer."

Licensing / partnership • Oncology